What Creyon Bio does

Creyon Bio is a privately held drug development company engineering oligonucleotide-based medicines (OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. The company combines two proprietary technology pillars: an aptamer-based delivery platform—anchored by a transferrin receptor (TfR) aptamer with validated preclinical proof-of-concept for crossing the blood-brain barrier—and the NuclelQ™ AI-powered nucleic acid engineering platform, which leverages proprietary pharmacology datasets and AI/ML predictive tools to design safe and active nucleic acid candidates. Creyon has three active wholly-owned programs, including a first-in-class splice-switching oligonucleotide therapy for late-onset Pompe disease and a CNS program enabled by BBB-crossing delivery; the platform is also being extended to direct lipid nanoparticles (LNPs) to immune and other cell types beyond oligonucleotides.

The company operates a licensing and partnership-driven business model rather than selling products directly. Revenue mechanics consist of upfront payments, development milestones, and royalties on partnered programs, anchored by a strategic partnership with Eli Lilly announced in 2025 valued at up to $1 billion for oligonucleotide therapeutics. Creyon is headquartered in San Diego, California with research operations in Research Triangle Park, North Carolina, and was launched in March 2022 with over $40 million in combined Seed and Series A funding co-led by DCVC Bio and Lux Capital. Customer base consists of large pharmaceutical partners rather than end patients or providers, with Eli Lilly named as the primary disclosed enterprise customer.

Name

Creyon Bio

Legal name

Creyon Bio

Website

https://creyonbio.com/

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Creyon Bio is a private drug development company engineering oligonucleotide-based medicines (OBMs) using aptamer delivery technology and its AI-powered NuclelQ platform for immunology, CNS, and neuromuscular diseases, generating revenue through pharmaceutical partnerships.

Ownership category

akta.pro rank

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. RNA-based Drug Development & Licensing: Creyon Bio is developing RNA-based medicines (OBMs) for treatment of immunology, CNS, and neuromuscular diseases. Revenue generation through licensing deals and eventual product commercialization for common and rare diseases.
2. Strategic Partnership Deals: Revenue through pharmaceutical partnerships such as the up to $1 billion deal with Eli Lilly for oligonucleotide therapeutics development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Creyon Bio is a drug development company engineering RNA-based medicines (Oligonucleotide-Based Medicines, or OBMs) for immunology, central nervous system (CNS), and neuromuscular diseases. Its approach combines the NuclelQ™ AI-powered nucleic acid engineering platform with proprietary aptamer-based delivery technology that targets specific cell types and can cross the blood-brain barrier, enabling tissue-specific delivery of siRNA and antisense oligonucleotides.

Product overview

Creyon Bio is a drug development company offering a platform-plus-technology approach to RNA-based medicine design. The core offering is the NuclelQ™ AI-Powered Nucleic Acid Engineering Platform, which uses proprietary pharmacology datasets and machine learning to design nucleic acid therapies. This platform is combined with the company's Aptamer Delivery Technology for cell-specific targeting, including the Transferrin Receptor (TfR) Aptamer for blood-brain barrier crossing. The company engineers Oligonucleotide-Based Medicines (OBMs) as precision drugs for immunology, CNS, and neuromuscular diseases. Creyon has three active wholly-owned products in its pipeline, including a late-onset Pompe disease therapy and a CNS program. The platform can direct both aptamers and lipid nanoparticles (LNPs) to immune and other cell types.

Differentiator

Problem solved

Functional benefit

Brands

• NuclelQ™: AI-Powered Nucleic Acid Engineering Platform that enables de-risked design of safe and active nucleic acid therapies using proprietary pharmacology datasets and AI/ML predictive tools.

Products and services

• Late-Onset Pompe Disease Therapy First-in-class splice-switching oligonucleotide therapy leveraging the TfR aptamer for targeted muscle delivery in late-onset Pompe disease; intended to restore endogenous acid alpha-glucosidase (GAA) production and sustain glycogen reduction. Developed by Creyon Bio as a wholly-owned drug candidate for partnership-based clinical advancement.
• CNS Program (TfR Aptamer-Mediated Delivery) Wholly-owned CNS pipeline program using the transferrin receptor (TfR) aptamer to shuttle siRNA and antisense oligonucleotides across the blood-brain barrier to disease-relevant targets in the brain. Preclinical proof-of-concept demonstrated; intended to support a broad set of CNS indications.
• Immunology Program (T and B Cell-Targeted OBMs) Wholly-owned immunology pipeline of OBMs designed for precise delivery of therapeutic payloads to T and B cells using proprietary aptamers, intended to modulate immune pathways and treat immune-driven diseases.

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

One partnership is on record.

• Eli LillycoreStrategic or Co-development Partner · 1 January 2025Eli Lilly partnership for oligonucleotide therapeutics worth up to $1 billion, including development milestones and royalties. Part of Lilly's broader AI-driven pharmaceutical strategy combining high-stakes discovery partnerships with pragmatic operational AI deployment. Creyon Bio contributes differentiated RNA drug design capabilities using its aptamer delivery platform and NuclelQ AI technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Dyne Therapeutics: Dyne develops targeted oligonucleotide therapies (siRNA, ASO) for serious muscle diseases (DM1, DMD, FSHD, Pompe) using its FORCE antibody fragment-targeted platform. Direct peer given shared focus on muscle-targeted nucleic acid delivery and overlap in Pompe disease, though Dyne uses antibody fragments rather than aptamer-based targeting.
• Avidity Biosciences: Avidity develops antibody-oligonucleotide conjugates (AOCs) for muscle and CNS diseases including DM1, DMD, FSHD, and rare metabolic disorders. Direct peer due to nearly identical therapeutic-area focus on neuromuscular/CNS indications and targeted delivery of nucleic acid payloads, although using antibody-based rather than aptamer-based targeting.
• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics with its TRiM targeting platform that enables extra-hepatic and tissue-directed delivery of siRNA. Direct peer in targeted nucleic acid delivery with multiple clinical-stage programs across liver, muscle, lung, and CNS.
• Wave Life Sciences: Wave develops stereopure oligonucleotide therapeutics including siRNA and antibody-oligonucleotide conjugate programs for CNS and rare diseases such as HD, ALS, and DMD. Direct peer with shared RNA chemistry platform emphasis and CNS focus area.
• Stoke Therapeutics: Stoke develops antisense oligonucleotide medicines that increase functional protein production via RNA splice modulation for severe genetic diseases (e.g., ADOA, Dravet). Direct peer given highly analogous splice-switching ASO therapeutic approach.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the leading siRNA therapeutics company with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and an extensive clinical pipeline across rare and common diseases. Broad incumbent that anchors the RNA therapeutics category in which Creyon competes.
• Ionis Pharmaceuticals: Ionis invented antisense oligonucleotide (ASO) therapeutics and commercializes multiple approved products (Spinraza, Tegsedi, Waylivra, Wainua). Broad incumbent with deep CNS and rare disease programs that overlaps directly with Creyon's splice-switching ASO and CNS delivery ambitions.

Emerging players

• Entrada Therapeutics: Entrada develops intracellular enzyme-based delivery technology for oligonucleotide and protein therapeutics in rare diseases including DM1 and DMD. Emerging player with comparable rare neuromuscular focus and distinctive delivery innovation.
• ProQR Therapeutics: ProQR develops Axiomer RNA editing therapeutics (siRNA-conjugate based) and other oligonucleotide treatments for rare diseases such as Rett syndrome. Emerging player with adjacent oligonucleotide platform technology addressing rare genetic diseases.

Others

• Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery platform company developing RNAi and mRNA therapeutics. Thematically adjacent peer given Creyon's stated LNP-targeting capability and shared focus on nucleic acid delivery innovation, though they do not directly compete in the same aptamer-based delivery niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/creyonbio
• LinkedInlinkedin.com/company/creyonbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creyon Bio